Income at Rs 1377 mn; PAT at Rs 326 mn
Suven Life Sciences, a biopharma company specialising in drug discovery and developmental activities in central nervous system disorders and Contract Research and Manufacturing Services (CRAMS) announced its unaudited financial results for the quarter ending June 30, 2016. The unaudited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on August 10, 2015 at Hyderabad.
Financial highlights for the first quarter ended June’ 2016 vs first quarter ended June 2015
Growth in revenue: Rs 1377 million vs Rs 1060 million – Up by 29.54 per cent
Growth in PAT: Rs 326 million vs Rs 206 million – Up by 58.12 per cent
Growth in EBIDTA: Rs 479 million vs Rs307 million – Up by 56.34 per cent
Financial highlights for the first quarter ended June’ 2016: (QoQ)
Growth in revenue: Rs 1377 million vs Rs 1694 million – Down by 20.81 per cent
Growth in PAT: Rs 326 million vs Rs 372 million – Down by 12.38 per cent
Growth in EBIDTA: Rs 479 million vs Rs 524 million – Down by 8.56 per cent
Suven’s thrust on innovative R&D in drug discovery continues with a spending of Rs 147 million (10.67 per cent on revenue) for the quarter ended June 30, 2016.
EP News Bureau – Mumbai
- Advertisement -
Comments are closed.